Submit Manuscript  

Article Details


Biologics for the Treatment of Juvenile Idiopathic Arthritis

[ Vol. 25 , Issue. 42 ]

Author(s):

Dimitri Poddighe*, Micol Romano, Maurizio Gattinara and Valeria Gerloni   Pages 5860 - 5893 ( 34 )

Abstract:


Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate the specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidence regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

Keywords:

Biologics, JIA, clinical evidence, immunology, pharmacodynamics, pharmacokinetics.

Affiliation:

Department of Medicine, School of Medicine, Nazarbayev University, Kerei-Zhanibek Str. 5/1, Astana, 010000, Department of Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza Card. Ferrari, 20126, Milano, Department of Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza Card. Ferrari, 20126, Milano, Department of Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza Card. Ferrari, 20126, Milano



Read Full-Text article